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e-mail address: k.tabbara@nesma.net.sa (K.F. Tabbara).Amr Nassar, MD a; Khalid F. Tabbara, MD b,⇑; Mahmoud Aljurf, MD, MPH cAbstractAllogeneic hematopoietic stem cell transplantation (HSCT) has evolved over the past two decades to become the standard of care
for hematologic and lymphoid malignancies. Major ocular complications after allogeneic HSCT have been increasing in number
and severity. Graft-versus-host disease (GVHD) remains a major cause of ocular morbidity after allogeneic HSCT. The main objec-
tive of this review is to elucidate the ocular complications in patients developing GVHD following HSCT.
Ocular complications secondary to GVHD are common and include dry eye syndrome, acquisition of ocular allergy from donors
with allergic disorders. Eyelid changes may occur in GVHD leading to scleroderma-like changes. Patients may develop poliosis,
madarosis, vitiligo, lagophthalmos, and entropion. The cornea may show filamentary keratitis, superficial punctate keratitis, cor-
neal ulcers, and peripheral corneal melting which may lead to perforation in severe cases. Scleritis may also occur which can be
anterior or posterior. Keratoconjunctivis sicca appears to be the most common presentation of GVHD. The lacrimal glands may
be involved with mononuclear cell infiltration of both the major and accessory lacrimal glands and decrease in tear production.
Severe dry eye syndrome in patients with GVHD may develop conjunctival scarring, keratinization, and cicatrization of the
conjunctiva.
Therapy of GVHD includes systemic immunosuppression and local therapy. Surgical treatment in refractory cases includes surgical
intervention to improve the manifestation of GVHD of the eye. This may include tarsorrhapy, prose lenses, punctal occlusions and
corneal transplantation.
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Hematopoietic stem cell transplantation (HSCT) has
evolved as a promising curative therapy for hematopoietic
disorders and some metabolic disorders. More recently,
HSCT has been investigated for its potential in establishing
tolerance for organ transplantation. For the treatment of
malignant disorders, the goal is to eradicate the cancer
through a combination of cytotoxic therapy and graft-ver-
sus-cancer effect. This approach is limited by conditioning in-
duced organ toxicity, graft-versus-host disease (GVHD), and
the ability of the malignancy to survive.1GVHD occurs when donor T cells respond to genetically
defined proteins on recipient host cells. The most important
proteins are Human Leukocyte Antigens (HLA) which are
highly polymorphic and are encoded by the major histocom-
patibility complex (MHC).2 Class I HLA (A, B, and C) proteins
are expressed on almost all nucleated cells of the body at
varying densities. Class II proteins (DR, DQ, and DP) on the
other hand, are primarily expressed on hematopoietic cells
(B cells, dendritic cells, and monocytes), but their expression
can be induced on many other cell types following inflamma-
tion or injury.3 Despite HLA matching identity between a
patient and donor, significant proportion of patients receiv-e:
al.com
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differences that lie outside the HLA loci, or ‘‘minor’’ histo-
compatibility antigens (HA).4,5 The release of cytokines from
tissues damaged by underlying disease, prior infections, and
the transplant conditioning regimen is believed to promote
the activation and proliferation of donor immune cells.6,7
Based largely on animal experimental models, the devel-
opment of acute GVHD can be described in three sequential
steps or phases: (1) activation of the antigen presenting cells
(APCs) by the cytokines released from damaged tissues, (2)
donor T cell activation, proliferation, differentiation and
migration; and (3) target tissue damage by activated T cells.8
Experimental studies have generated several theories to
explain the pathophysiology of chronic graft-versus-host-dis-
ease (cGVHD): (1) Thymic damage and the defective negative
selection of T cells, (2) Regulatory T cell deficiencies, (3) auto-
antibody production by aberrant B cells, and (4) the forma-
tion of profibrotic lesions.9
Chronic GVHD (cGVHD) remains the most common late
complication of allogeneic stem cell transplantation (SCT).
Although improvements have been made in the prevention
of acute GVHD, these advances have not been reflected on
the incidence of cGVHD.10 Several factors have contributed
to the high incidence of cGVHD including increased upper
age limit of transplant recipients, use of unrelated donors
and incomplete HLA matched related donors, use of periph-
eral blood as a source of stem cells, and use of donor lym-
phocyte infusion to treat relapsed disease or to achieve full
donor chimerism.11Table 1. Major ocular complications following Hematopoietic Stem Cell
Transplantation (HSCT) among 620 patients.21
No. (%)
Graft-versus-host-disease 34 (5.4)
Dry eye syndrome 30 (4.8)
Corneal ulcers 15 (2.4)
Steroid-induced cataract/glaucoma 10 (1.6)
Infectious retinitis 4 (0.6)
Acquisition of allergic conjunctivitis 4 (0.6)
Other (uveitis, endophthalmitis) 4 (0.6)Clinical presentation and staging of Graft-versus-host-
disease (GVHD)
Graft-versus-host-disease (GVHD) occurring from the day
of transplantation (day 0) to day 100 after the transplantation
is referred as ‘‘acute’’ GVHD, whereas GVHD occurring after
day 100 is termed ‘‘chronic’’ GVHD. These divisions, how-
ever, are thought to be relatively arbitrary, as acute and
chronic patterns of GVHD can occur in chronic and acute set-
tings, respectively.12 Acute patterns of GVHD include skin
bullae desquamation, severe bile duct injury, and extensive
gastrointestinal crypt drop-out.13 Chronic GVHD features
are more complex, including clinical manifestations of mixed
autoimmune disorders, with the hallmark of excessive fibro-
sis, stenosis, and atrophy of tissues in the skin, lung, and mu-
cous membranes (mouth, vagina, and eyes).14 Acute GVHD
has historically been graded by the culmination of the GVHD
staging systems for three organs (skin, gastrointestinal tract,
and liver).15 Chronic GVHD can be classified according to the
type of onset, need for systemic immunosuppressive therapy,
or mortality risk. The majority of patients with chronic GVHD
have suffered from acute GVHD. Their disease may evolve di-
rectly from acute GVHD (progressive) that has a bad progno-
sis, or may follow a period of resolution (quiescent or
interrupted), with an intermediate prognosis. Patients may
develop chronic GVHD with no history of acute GVHD (de
novo) which usually have a good prognosis.16 Based on data
from the International Bone Marrow Transplant Registry
(IBMTR), the distribution of chronic GVHD onset for HLA-
matched siblings is progressive in 20–30%, interrupted in
30–40% and de novo in 35% of patients.17 The most com-
monly employed staging system is the ‘limited/extensive’classification, proposed by the Seattle group in 1980, based
on a retrospective clinical and pathological review of 20 pa-
tients with chronic GVHD.18 Localized skin involvement with
or without hepatic dysfunction (limited disease) was associ-
ated with less severe disease and decreased rate of infec-
tions. Generalized skin involvement or limited disease with
eye involvement, oral involvement, hepatic dysfunction with
abnormal liver histology, or involvement of any other target
organ was classified as extensive disease and was associated
with more frequent infections.19 The Seattle group has devel-
oped the revised clinical criteria for limited and extensive
chronic GVHD in order to clarify ambiguities of the original
definition. In the revised classification, prolonged treatment
with systemic immunosuppression is indicated for patients
with clinically extensive chronic GVHD or anyone with high-
risk features (i.e., platelets count <100  109/l, progressive
onset, or receiving treatment with corticosteroids at the time
of the diagnosis of chronic GVHD).14
Ocular manifestations of GVHD
Acquisition of ocular allergy occurred in patients receiving
HSCT from donors with allergic disorders.20 Ocular complica-
tions secondary to GVHD are frequent. Major ocular compli-
cations occurred in 80 (13%) of 620 patients after HSCT
(Table 1). The most common ocular complication was
cGVHD.21 While ocular GVHD usually occurs in the setting
of other systemic GVHD, it may also be the initial presenta-
tion of the patient’s systemic GVHD. The eye may be involved
in both acute and chronic GVHD, although it is more common
in the chronic form of the disease with more severe
presentation.22
The National Institutes of Health (NIH) working group pub-
lished consensus document to establish standardized criteria
for the diagnosis of cGVHD and to propose tools for scoring
cGVHD organ involvement and assessing overall severity
(Table 2).
According to this consensus document, the diagnosis of
cGVHD requires: (1) distinction from acute GVHD as well as
other possible diagnoses, and (2) the presence of at least
one diagnostic clinical sign of cGVHD or the presence of at
least one distinctive manifestation confirmed by pertinent
biopsy or other relevant tests.23 For cGVHD of the eye, there
is no recommendation for obtaining samples for histopatho-
logic diagnosis. However, distinctive manifestations of
cGVHD include new onset of dry, gritty, or painful eyes, cic-
atricial conjunctivitis, keratoconjunctivitis sicca, and confluent
areas of punctate keratopathy. Other features include photo-
phobia, periorbital hyperpigmentation, difficulty in opening
the eyes in the morning because of mucoid secretions, and
blepharitis. New ocular sicca documented by low Schirmer
test values with a mean value of both eyes 65 mm at 5 min
Table 2. NIH consensus criteria: Ocular GVHD staging.
Score Definition
0 No symptoms
1 Mild dry eye symptoms not affecting daily activities (requiring eye drops 63x per day) or asymptomatic signs of KCS
2 Moderate dry eye symptoms partially affecting daily activities (requiring drops >3x per day or punctal plugs) without vision impairment
3 Severe dry eye symptoms significantly daily activities (special eyewear to relieve pain) or unable to work because of ocular symptoms or loss
of vision caused by KCS
GVHD: Graft-versus-host disease; KCS: Keratoconjunctivitis sicca; NIH: National Institutes of Health.
Figure 3. A 32 year-old male developed GVHD. He had bilateral
conjunctivitis and dry eye syndrome.
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ination with mean values of 6 to 10 mm on the Schirmer test
is sufficient for the diagnosis of chronic GVHD, if accompa-
nied by distinctive manifestations in at least one other
organ.23 (Figs. 1–3).
Inamoto Y et al. tried to validate the measurement scales
in ocular graft-versus-host- disease.24 They recommended
using the NIH eye score to assess response in clinical trials
for chronic GVHD because it is easy, quick and non-sophisti-
cated test (Table 2). Besides, it correlates well with both clini-
cian- and patient-reported symptom changes.24
Several other studies are in agreement with such recom-
mendations because of the low reproducibility of Schirmer
test and the inter- and intra-rater variability in reporting the
severity of symptoms.25–27
Ocular GVHD is a spectrum of clinical manifestations,
affecting all layers of the eye, including the lid, lacrimal gland,Figure 1. Graft-versus-host-disease (GVHD) with keratoconjunctivitis
sicca showing cutaneous changes with scleroderma-like skin lesions and
areas of pigmentations and depigmentations.
Figure 2. Dry eye syndrome with entropion and loss of eyelashes in
GVHD.conjunctiva, cornea, and even the vitreous and the choroids,
although the posterior involvement of ocular GVHD is
exceedingly rare.28 Posterior scleritis, choroidal thickening,
and serous detachments that respond to high-dose steroid
are manifestations of ocular acute GVHD.29 Keratoconjuncti-
vitis sicca appeared to be more severe in patients with GVHD
than in patients without GVHD21 (Table 1).
Eyelid skin changes are similar to skin findings in acute
GVHD and include maculopapular, erythematous exanthema.
The cutaneous manifestations of GVHD may affect the eye-
lids. Dermatitis, lagophthalmos, ectropion, poliosis, madaro-
sis, and vitiligo have been reported in cGVHD28 (Figs 1 and
2]. Anterior segment manifestations of acute GVHD include
conjunctivitis, anterior uveitis, superior limbic keratoconjunc-
tivitis, and episcleritis30–32 (Fig. 3).Conjunctiva
Conjunctival involvement in acute GVHD is rare, but when
present, it is a poor prognostic factor and is a marker for se-
vere systemic involvement. Conjunctival disease ranges from
mild erythema to pseudomembranous and cicatrizing con-
junctivitis similar to ocular cicatricial pemphigoid33 (Fig. 4).
The conjunctivitis of acute GVHD is more often ulcerative
and hemorrhagic. Several hemorrhagic stage episodes alter-
nating with exudative stages, which are characterized by ster-
ile, purulent discharge of polymorphonuclear leukocytes with
pseudomembrane formation may show ulceration and laser
scarring, and fibrosis of the conjunctiva.33
In the chronic form of GVHD, dry eye is the most frequent
complication occurring in 40% to 76% of patients and its
severity is correlated to the severity of cGVHD.21,34 The main
cause of keratoconjunctivitis sicca in GVHD is lymphocytic
infiltration of the accessory and major lacrimal glands. This
may lead to fibrosis of the acini and ductules.34 Additionally,
Figure 4. Conjunctival cicatrization and shrinkage in a patient with
GVHD.
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gland dysfunction, and the underlying disease process may
all contribute to dry eyes in GVHD patients.21 In most pa-
tients, keratoconjunctivitis sicca persists after the remission
of GVHD. Patients with aqueous tear deficiency may rarely
have normal tear function after 4 years of follow-up.31,32 Sev-
eral complications may follow, such as punctate keratitis, cor-
neal filaments, persistent epithelial defects, corneal
keratinization, ulceration, and perforation in spite of ade-
quate tear substitutes35 (Fig. 5). A characteristic non-infec-
tious pseudomembranous conjunctivitis has been described
in association with GVHD.31,32 Four stages of conjunctival
GVHD were described. Stage 1 is conjunctival hyperemia
without other changes. Stage 2 includes a chemotic response
or serosanguinous exudates or both. Stage 3 is characterized
by the presence of conjunctival pseudomembranes and
Stage 4 disease occurs when patients with pseudomembra-
nous conjunctivitis undergo cicatrization and conjunctival
shrinkage with loss of the corneal epithelium and indolent
corneal ulcer.
Although patients may progress consecutively from lower
to higher stages, they frequently present with Stage 3 dis-
ease. Development of Stage 4 ocular GVHD was found to
be associated with a more severe form of both acute and
chronic systemic GVHD.33Figure 5. An 18 year-old female who developed GVHD following bone
marrow transplantation. Figure shows keratoconjunctivitis sicca and
corneal filaments.Corneal involvement
Corneal involvement is found typically more commonly in
cGVHD than in acute GVHD. In acute GVHD, there may be
corneal epithelial keratitis or filamentary keratitis secondary
to the conjunctival cicatrization, but not a direct cause and ef-
fect of graft-versus-host tissue reaction. Rarely, peripheral
corneal melting occurs which may lead to corneal perfora-
tion21,32 (Fig. 6).
Chronic GVHD is commonly associated with keratocon-
junctivitis sicca. The dry eye of GVHD is often severe and
can lead to filamentary keratitis, corneal neovascularization,
corneal ulceration, melting of the cornea, and ultimately cor-
neal perforation if not treated36 (Fig. 6).Lacrimal Gland involvement
In cGVHD disease, there is a histologic evidence of mono-
nuclear cell infiltration of the major and accessory lacrimal of
Kraus and Wolfring leading to tear dysfunction. T cell medi-
ated cytotoxic effects may damage the periductal epithelial
cells which impair the lacrimal gland exocrine functions.34
The mononuclear infiltration is similar to the findings seen
in Sjögren syndrome. Subsequent fibrosis may occur result-
ing in irreversible dry eye syndrome (Fig. 7).
Lacrimal gland dysfunction probably is the most common
ocular manifestation of ocular GVHD. Histopathologic analy-
sis demonstrates periodic acid-Schiff-positive material clog-
ging and distending lacrimal gland ducts, further impairing
the ability to secrete tears. In addition to lacrimal gland dys-
function, the presence of cicatricial lagophthalmos or ectro-
pion may lead to poor tear film distribution and abnormal
ocular surface disease.35–37 The labial accessory salivary
glands show mononuclear infiltration similar to the changes
in the lacrimal glands (Fig. 7).Cataract
Increased cataract formation has been noted in patient
post-HSCT, but this is thought to be related to treatment
with corticosteroids or total body irradiation, not as a result
of the GVHD reaction in itself.21,38–42 Patients with ocular
GVHD who have developed cataracts may undergo phacoe-Figure 6. Peripheral corneal melting in a patient with GVHD and dry eye
syndrome.
Figure 7. Labial Accessory salivary gland in a patient with GVHD showing
mononuclear cell infiltration surrounding ductules with destruction of
salivary acini.
Ocular manifestations of graft-versus-host disease 219mulsification with intraocular lens implantation as long as
their ocular surface disease is adequately managed.40
Posterior segment manifestations
A variety of posterior segment complications may be seen
in GVHD patients. Micro-vascular retinopathy with cotton-
wool spots, intra-retinal and vitreous hemorrhage, and infec-
tion may occur, which may be related to the initial disease, its
treatment or conditioning regimen.43
Central serous chorioretinopathy (CSCR) is an uncommon
complication in HSCT patients.44,45 Because of its response
to systemic corticosteroids, it was suggested that GVHD it-
self may affect the choroidal vasculature, leading to choroidal
hyperpermeability and the development of CSCR.46
Posterior scleritis has been reported to be associated with
GVHD.45,46 Vitritis is an uncommon manifestation of GVHD.47
Systemic Therapy
Although systemic immune suppression is the corner
stone in the management of GVHD, the role of topical treat-
ment cannot be overlooked. Local treatment modalities
might be needed even if systemic therapy is not indicated.48
Acute ocular GVHD can be treated as part of systemic dis-
ease without the need for local modalities. However, in Stage
2 pseudo-membranous conjunctivitis, topical steroids, cyclo-
sporine or tacrolimus may reduce cicatricial and fibrovascular
scarring and prevent progression to Stage 4 disease. Calci-
neurin inhibitors are found to ameliorate the sequential signs
and manifestations of chronic ocular GVHD.49–51
In chronic ocular GVHD, several systemic therapeutic
modalities are available including steroids, as cyclosporine
A and mycophenolate mofetil, and agents targeting B-cells
such as rituximab.49 Systemic tacrolimus has shown efficacy
in lacrimal gland dysfunction secondary to ocular chronic
GVHD.52
Several committees have published guidelines for the
management of cGVHD including National Institutes of
Health (NIH) consensus development project, Consensus
Recommendations of Experts from Germany, Austria, and
Switzerland, the British Committee for Standards in Haema-
tology, and the British Society for Bone Marrow
Transplantation.48,53,54Corticosteroids are usually recommended as a first line
therapy based on randomized trial.54 Most guidelines recom-
mend a prednisolone dose of 1 mg/kg/day for 2 weeks with
gradual tapering to 1 mg/kg every other day over 6–8 weeks
and then tapered by 10–20% per month for a total duration
of 9 months48,53–55
This regimen was also combined with additional immuno-
suppressive therapy like cyclosporine and mycophenolate
mofetil. In such patients who are receiving other immunosup-
pressive agents, it is recommended to start tapering off ste-
roids first. Other immunosuppressive agents can be tapered
one at a time over a 3–9 month period with dose reductions
every 2–4 weeks depending on clinical response. The median
duration of immunosuppressive therapy is 2–3 years.56 With
prolonged steroid therapy for cGVHD, patients and physician
should be aware of the hazards of developing cataract as well
as bone density loss, infectious diseases and other
complications.
Second-line therapy for steroid refractory GVHD is based
on only phase II trials and retrospective analyses.57 Several
agents can be used in combination with each other in such
case. In general, no more than three immunosuppressive
agents should be combined, as combination of more drugs
often does not lead to improved efficacy but results in a sig-
nificantly increased risk of side effects and infections.57
Improved tear secretion, improved ocular surface findings
and increase in Schirmer test values were reported with sys-
temic tacrolimus therapy.58,59 In addition steroid sparing
agents might allow steroid dose reduction with substantial
reduction of toxicity.57
The systemic immunosuppression must be optimally ti-
trated and maximized when ocular GVHD with systemic
GVHD (skin, liver, and gut) is not controlled. The ideal ap-
proach to the local and systemic management of ocular
GVHD is a multidisciplinary approach with the proper under-
standing of the patient’s overall GVHD clinical status.53Local Therapy
The National Institutes of Health cGVHD consensus work-
shop had recently summarized the management of cGVHD,
including chronic ocular GVHD. The group emphasized the
importance of organ specific treatment in addition to the sys-
temic immune suppression.48
Although systemic immunosuppressive therapies for
chronic GVHD can improve dry eye symptoms, functional
improvement might be limited, especially if lacrimal gland
dysfunction has been long term.60
The aim of supportive care for the eye is to lubricate and
decrease tear from the surface of the eye, hence improving
ocular surface moisture and decreasing ocular surface inflam-
mation and minimize the need for increasing systemic immu-
nosuppressive therapy.Decreasing Ocular Surface Inflammation
Judicious use of topical steroids to decrease ocular surface
inflammation may be necessary. Usually local immunosup-
pressants are reserved for the control of ocular GVHD exac-
erbation that might happen during tapering of systemic
immunosuppression, control of conjunctival inflammation
associated with cicatricial conjunctivitis, and in the early treat-
220 A. Nassar et al.ment of Stage 4 acute ocular GVHD.60 Topical steroids help
to avoid adverse events of prolonged intense systemic im-
mune suppression and maximize the benefit of GVL
effect.61,62 However, its use carries the risk of steroid-related
complications which include increased intraocular pressure,
cataract formation, and silent infectious keratitis.60
Topical cyclosporine can decrease surface ocular inflam-
mation and inhibit surface apoptosis but with minimal effect
on lacrimal gland function.63–65
Ocular surface inflammation may also be decreased with
autologous and allogeneic serum eye drops, but this treat-
ment is not available for a wide scale use.66,67
The use of preservative-free artificial tears has been shown
to minimize superficial punctuate keratopathy and improve
the quality of vision by coating and protecting the integrity
of the ocular surface.68
Slowly dissolving preparations like 5-mg pellets of
hydroxypropyl methylcellulose might decrease the rate of
application from once hourly to twice per day and is more
convenient.69 Hydroxypropyl cellulose ophthalmic inserts
are reported to improve the symptoms of dry eye, ability to
perform activities of daily living, and quality of life.70
Although some oral medications (as selective muscarinic
agonists such as cevimeline or pilocarpine) increase lubrica-
tion by stimulating aqueous tear flow in autoimmune dis-
eases, yet drug interactions, toxicities and patient comorbid
conditions might limit therapeutic benefit in cGVHD.71
Meibomian glands produce the outer oil layer of the tear
film. Measures to maximize the output of meibomian glands
include warm compresses, lid care and use of moisture cham-
ber goggles to minimize local evaporation.72 Doxycycline can
be used to treat rosacea blepharitis thereby decreasing
inflammation and evaporation.73
Several types of contact lenses have been used in ocular
GVHD to reduce friction pain and control evaporation from
the inflamed surface including silicon hydrogel, rigid, and
gas permeable scleral contact lenses.74Surgical treatment
In refractory cases, several surgical interventions improve
the manifestations of cGVHD of the eye. Tarsorrhaphy de-
creases the exposed surface area, minimizing dryness and
evaporation.75 Scleral lenses may also be beneficial in severe
cases, but this treatment is available in only a limited number
of centers.76
Temporary or permanent occlusion of the tear-duct punc-
ta may provide additional benefit for patients with severe
ocular GVHD to decrease drainage from the surface of the
eye. As the temporary occlusion fall out repeatedly, perma-
nent punctal occlusion by lacrimal punctal cauterization was
effective with no recanalization and significant improvements
in subjective symptoms and the ocular surface environment in
cGVHD-related dry eye.77
Patients with cGVHD related severe dry eyes and calcare-
ous corneal degeneration, even with little perforation may
benefit from multilayer amniotic membrane transplantation.
It may be considered as an alternative for reconstruction of
the ocular surface in such patients.78,79 Lamellar or penetrat-
ing keratoplasty can be used to correct defects secondary to
eye involvement like corneal ulceration or perforation.80Amniotic membranes may be used for cases with indolent
corneal ulcers.
Frequent recurrences and severe dessication are the major
drawback of these surgeries.81 Episcleral cyclosporine A im-
plants had been tested in several immune mediated disor-
ders in the eye, such as uveitis and in high-risk keratoplasty
rejection. However, its broad utilization in cGVHD of the
eye is still under investigations with promising results.82Conclusion
Graft-versus-host disease (GVHD) remains a major cause
of morbidity and mortality after allogeneic hematopoietic
stem cell transplantation. Ocular GVHD is a major cause of
long-term morbidity in GVHD. The diagnosis and treatment
of acute and chronic systemic GVHD require a multidisciplin-
ary approach for optimal outcome, probably through a com-
bined hematology and ophthalmology visits. Tailoring the
immunosuppression, proper assessment of the response
and utilization of maximal local and topical measures can im-
prove the ability to perform activities of daily living and en-
hance the quality of life.Conflict of interest
The authors declared that there is no conflict of interest.
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